Praxis Precision Medicines (PRAX) COO discloses share and option stake
Rhea-AI Filing Summary
Praxis Precision Medicines, Inc. (PRAX) filed an initial ownership report for Chief Operating Officer Megan Sniecinski as of January 1, 2026. She beneficially owns 20,877 shares of common stock, which include unvested restricted stock units that settle in common shares. In addition, she holds multiple stock options covering blocks of common stock at exercise prices ranging from $31.8 to $257.25, with vesting schedules spanning several years and expirations extending to 2035. All reported holdings are listed as directly owned.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Includes: (i) 5,805 unvested Restricted Stock Units ("RSUs") from an award of 7,800 RSUs granted on July 29, 2024, which vests in equal annual installments over a four-year period beginning on January 12, 2025; and (ii) 11,250 RSUs granted on January 10, 2025, which vests in equal annual installments over a four-year period beginning on January 10, 2026. The RSUs may be settled only by delivering shares of the Issuer's common stock, and thus, both grants are being reported in Table 1 as allowed per SEC guidance. This option is fully vested. The shares underlying this stock option vest over a four-year period, with 25% vested on June 22, 2023 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. The shares underlying this stock option vest over a four-year period, with 25% vested on January 12, 2024 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. The shares underlying this stock option vest as follows: 50% vested in full on January 12, 2024 (the "Grant Date") and the remaining 50% vesting over a four-year period, with 25% of such shares vesting on the first anniversary of the Grant Date and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the reporting person's continued service through each vesting date. The shares underlying this stock option vest over a four-year period, with 25% vesting on January 10, 2026 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date.
FAQ
What does the Form 3 filing for PRAX disclose about insider Megan Sniecinski?
The Form 3 shows that Chief Operating Officer Megan Sniecinski beneficially owns 20,877 shares of common stock and several stock option awards, all reported as directly owned.
What stock options are reported by the PRAX Chief Operating Officer?
The filing lists multiple stock options (rights to buy common stock), including grants for 11,999, 821, 9,999, 30,000, 36,400, and 22,500 shares, each with its own exercise price and vesting schedule.
What are some exercise prices of the PRAX stock options held by the COO?
The reported stock options have exercise prices including $257.25, $31.8, $44.4, $43.37, $56.94, and $63.15 per share of Praxis common stock.
How do the RSUs reported in the PRAX Form 3 vest for the COO?
The RSUs include 5,805 unvested RSUs from a July 29, 2024 grant that vests in equal annual installments over four years beginning January 12, 2025, and 11,250 RSUs from a January 10, 2025 grant vesting annually over four years beginning January 10, 2026.
Do the PRAX stock options reported by the COO have multi-year vesting schedules?
Yes. Several options vest over four-year periods, often with 25% vesting on an initial date (such as June 22, 2023, January 12, 2024, or January 10, 2026) and the remaining 75% in 36 monthly installments, subject to continued service.
Is any PRAX stock held indirectly or through another entity in this Form 3?
No. All reported common stock and stock options for Megan Sniecinski in this Form 3 are shown with direct (D) ownership and no separate indirect ownership entity is listed.